全文获取类型
收费全文 | 203045篇 |
免费 | 3746篇 |
国内免费 | 2146篇 |
专业分类
耳鼻咽喉 | 1341篇 |
儿科学 | 7000篇 |
妇产科学 | 3329篇 |
基础医学 | 19674篇 |
口腔科学 | 2061篇 |
临床医学 | 16159篇 |
内科学 | 34837篇 |
皮肤病学 | 915篇 |
神经病学 | 17714篇 |
特种医学 | 10099篇 |
外国民族医学 | 13篇 |
外科学 | 31901篇 |
综合类 | 7114篇 |
现状与发展 | 6篇 |
一般理论 | 3篇 |
预防医学 | 19856篇 |
眼科学 | 3395篇 |
药学 | 12491篇 |
29篇 | |
中国医学 | 2218篇 |
肿瘤学 | 18782篇 |
出版年
2024年 | 82篇 |
2023年 | 389篇 |
2022年 | 959篇 |
2021年 | 1382篇 |
2020年 | 1024篇 |
2019年 | 948篇 |
2018年 | 22796篇 |
2017年 | 18208篇 |
2016年 | 20357篇 |
2015年 | 2191篇 |
2014年 | 2370篇 |
2013年 | 2180篇 |
2012年 | 8811篇 |
2011年 | 23183篇 |
2010年 | 20199篇 |
2009年 | 12599篇 |
2008年 | 20864篇 |
2007年 | 23139篇 |
2006年 | 1974篇 |
2005年 | 3560篇 |
2004年 | 4404篇 |
2003年 | 5400篇 |
2002年 | 3433篇 |
2001年 | 1115篇 |
2000年 | 1194篇 |
1999年 | 902篇 |
1998年 | 626篇 |
1997年 | 702篇 |
1996年 | 417篇 |
1995年 | 392篇 |
1994年 | 329篇 |
1993年 | 247篇 |
1992年 | 262篇 |
1991年 | 295篇 |
1990年 | 303篇 |
1989年 | 237篇 |
1988年 | 185篇 |
1987年 | 171篇 |
1986年 | 136篇 |
1985年 | 104篇 |
1984年 | 68篇 |
1983年 | 48篇 |
1982年 | 40篇 |
1980年 | 64篇 |
1979年 | 47篇 |
1974年 | 39篇 |
1938年 | 61篇 |
1934年 | 31篇 |
1932年 | 60篇 |
1930年 | 47篇 |
排序方式: 共有10000条查询结果,搜索用时 750 毫秒
81.
Kentaroh Miyoshi Minoru Naito Tsuyoshi Ueno Shinji Hato Hideo Ino 《General thoracic and cardiovascular surgery》2009,57(11):629-632
A benign esophageal leiomyoma with abnormally increased fluorine-18-fluorodeoxyglucose uptake on positron emission tomography
(PET) was resected thoracoscopically. The tumor, of which the maximum standardized uptake value of the lesion was 4.7, was
well defined and 38 mm in diameter. Neither mitotic activity nor degeneration was found histologically; and immunoreactivity
for CD34, CD117, MIB-1, and glucose transporter-1 was negative immunohistochemically. A diagnosis of gastrointestinal stromal
tumor was ruled out by an oncogenic kinase gene mutation study. This case cautions against PET-dependent evaluation for malignant
potential of esophageal submucosal tumors. 相似文献
82.
83.
Timothy M. Pawlik Kelly Olino Ana Luiza Gleisner Michael Torbenson Richard Schulick Michael A. Choti 《Journal of gastrointestinal surgery》2007,11(7):860-868
Some investigators have suggested that preoperative chemotherapy for hepatic colorectal metastases may cause hepatic injury
and increase perioperative morbidity and mortality. The objective of the current study was to examine whether treatment with
preoperative chemotherapy was associated with hepatic injury of the nontumorous liver and whether such injury, if present,
was associated with increased morbidity or mortality after hepatic resection. Two-hundred and twelve eligible patients who
underwent hepatic resection for colorectal liver metastases between January 1999 and December 2005 were identified. Data on
demographics, clinicopathologic characteristics, and preoperative chemotherapy details were collected and analyzed. The majority
of patients received preoperative chemotherapy (n = 153; 72.2%). Chemotherapy consisted of fluoropyrimidine-based regimens: 5-FU monotherapy, 31.6%; irinotecan, 25.9%; and
oxaliplatin, 14.6%. Among those patients who received chemotherapy, the type of chemotherapy regimen predicted distinct patterns
of liver injury. Oxaliplatin was associated with increased likelihood of grade 3 sinusoidal dilatation (p = 0.017). Steatosis >30% was associated with irinotecan (27.3%) compared with no chemotherapy, 5-FU monotherapy, and oxaliplatin
(all p < 0.05). Irinotecan also was associated with steatohepatitis, as two of the three patients with steatohepatitis had received
irinotecan preoperatively. Overall, the perioperative complication rate was similar between the no-chemotherapy group (30.5%)
and the chemotherapy group (35.3%) (p = 0.79). Preoperative chemotherapy was also not associated with 60-day mortality. In patients with hepatic colorectal metastases,
preoperative chemotherapy is associated with hepatic injury in about 20 to 30% of patients. Furthermore, the type of hepatic
injury after preoperative chemotherapy was regimen-specific.
Presented at the American Hepato-Pancreato-Biliary Association 2006 Annual Meeting, March 11, Miami, Florida. 相似文献
84.
Yulu Miao Mingxia Zhang Yulin Nie Wan Zhao Bin Huang Zhengming Jiang Shaoxiong Yu Zhibin Huang Hongjin Fu 《中国神经再生研究》2007,2(2):126-128
BACKGROUND: Besides local changes of cranial parenchymal cells, hemorrhage, etc., severe traumatic brain injuries also cause the changes of total body fluid and various functions, and the changes of lymphocytes and T lymphocyte subsets should be paid more attention to. OBJECTIVE: To reveal the changing laws of T lymphocyte subsets after severe traumatic brain injury, and compare with mild to moderate brain injury. DESIGN: A comparative observation. SETTINGS: Department of Neurosurgery, Longgang District Buji People's Hospital of Shenzhen City; Central Laboratory of Shenzhen Hospital of Prevention and Cure for Chronic Disease. PARTICIPANTS: All the subjects were selected from the Department of Neurosurgery, Longgang District Buji People's Hospital of Shenzhen City from August 2002 to August 2005. Thirty patients with severe brain injury, whose Glasgow coma score (GCS) was ≤ 8 points, were taken as the experimental group, including 21 males and 9 females, aging 16 - 62 years. Meanwhile, 30 patients with mild traumatic brain injury were taken as the control group (GCS ranged 14- 15 points), including 18 males and 12 females, aging 15 -58 years. All the subjects were in admission at 6 hours after injury, without disease of major organs before injury Informed consents were obtained from all the patients or their relatives. METHODS: (1) The T lymphocytes and the subsets in peripheral blood were detected with immunofluorescent tricolor flow cytometry at l, 3, 7 and 14 days after injury in both groups. (2) The conditions of pulmonary infections were observed at 4 days after injury. The differences of measurement data were compared with the t test. MAIN OUTCOME MEASURES: Changes of T lymphocytes subsets at 1 - 14 days after severe and mild or moderate traumatic injury. RESULTS: Finally, 28 and 25 patients with mild to moderate traumatic brain injury, whereas 25 and 21 patients with severe traumatic brain injury were analyzed at 7 and 14 days respectively, and the missed ones died due to the development of disease. (1) Changes of T lymphocyte subsets: At 1 and 3 days after injury, CD3, CD4, CD8, CD4/CD8 began to decrease, whereas CD8 increased in the experimental group, which were very significantly different from those in the control group (t =2.77 - 3.26, P 〈 0.01), and began to recover at 7 days, which were significantly different from those in the control group (t = 2.06 - 2.24, P 〈 0.05), and generally recovered to the normal levels at 14 days (P 〉 0.05). (2) Conditions of pulmonary infections: At 4 days after injury, the rate of pulmonary infection was significantly different between the experimental group and control group [73% (22/30), 0, x2=37.29, P 〈 0.01]. CONCLUSION: Patients with severe traumatic brain injury suffer from damages of cellular immune function at early period (within 7 days), and they are easily to be accompanied by pulmonary infections. 相似文献
85.
Simon Bell Andrew J McLachlan Parisa Aslani Paula Whitehead Timothy F Chen 《Australia and New Zealand Health Policy》2005,2(1):29
The objective of this systematic review was to evaluate the impact of pharmacist delivered community-based services to optimise the use of medications for mental illness. Twenty-two controlled (randomised and non-randomised) studies of pharmacists' interventions in community and residential aged care settings identified in international scientific literature were included for review. Papers were assessed for study design, service recipient, country of origin, intervention type, number of participating pharmacists, methodological quality and outcome measurement. Three studies showed that pharmacists' medication counselling and treatment monitoring can improve adherence to antidepressant medications among those commencing treatment when calculated using an intention-to-treat analysis. Four trials demonstrated that pharmacist conducted medication reviews may reduce the number of potentially inappropriate medications prescribed to those at high risk of medication misadventure. The results of this review provide some evidence that pharmacists can contribute to optimising the use of medications for mental illness in the community setting. However, more well designed studies are needed to assess the impact of pharmacists as members of community mental health teams and as providers of comprehensive medicines information to people with schizophrenia and bipolar disorder 相似文献
86.
Statutory reimbursement agencies as well as private insurers throughout member states of the Organization for Economic Cooperation and Development (OECD) reimburse the cost of medicines on the basis of criteria that include robust clinical evidence, budget impact analysis, and incremental cost effectiveness. The Centers for Medicare and Medicaid Services (CMS) in the US are no exception to this rule and are, in principle, seeking to maximize benefit for their Medicare enrollees, whilst ensuring reasonable drug outlays for the small number of drugs that they reimburse. This paper provides a retrospective analysis of the way two functionally equivalent drugs are treated for reimbursement purposes by the CMS; the period under consideration was 2001–3. The two drugs, epoetin-α and darbepoetin-α, are used for the treatment of anemia in renal failure and in patients receiving chemotherapy. By reviewing the publicly available pharmacological and clinical data of epoetin-α and darbepoetin-α, the paper confirms the two drugs’ functional equivalence, despite their structural differences. The implications of dose conversion ratios and costs to Medicare are subsequently explored. It is argued that the issue of dose equivalence between epoetin-α and darbepoetin-α has significant implications for patients, practitioners, and payors. A payor’s perspective is adopted in this respect, whereby clinical evidence and pricing data are used simultaneously. Based on the clinical evidence, a dose conversion ratio for epoetin-α:darbepoetin-α is established, which achieves a comparable clinical effect for the two drugs and this is set to be <254IU:1μg. The incremental costs to Medicare are calculated subsequently. The Average Wholesale Price and the Outpatient Prospective Payment System rule that Medicare uses to reimburse providers are used and suggest that treatment of cancer patients with chemotherapy-related anemia with epoetin-α would save Medicare an estimated $US600 million each year. Patients would also benefit significantly in terms of lower co-payments for epoetin-α. The evidence is supportive of the decision made by the CMS to reimburse the two drugs at the rate reflecting the achievement of comparable clinical effects and therefore reducing the pass-through payments for darbepoetin-α to zero for the 2002–3 fiscal year. 相似文献
87.
Objective: To study the diagnostic value of T2^*-weighted first-pass perfusion imaging in breast tumors. Methods: We analyzed the magnetic resonance imaging (MRI) information along with the pathological and immunohistochemistry results. Magnetic resonance imaging was performed in 28 patients with breast tumor. The time to signal intensity curves were generated according to the T2^*-weighted first-pass perfusion imaging. The curve's maximal signal intensity drop rate and maximal signal intensity decrease time were analyzed and compared with the pathological diagnoses after surgery. Results: Malignant breast lesions showed higher maximal signal intensity drop rate (44.69% ± 17.07 vs. 17.22% ±7.49, P 〈 0.001) than benign lesions, but there was no significant difference of maximal signal decrease time between those two lesions (23.94 s ± 4.92 vs. 20.02 s ± 6.83, P 〉 0.05). Conclusion: The T2^*-weighted first-pass perfusion imaging has enough sensitivity and specificity in breast tumor diagnosis. 相似文献
88.
89.
以钒基核苷酸复合物为核酸酶抑制剂,从人胚组织中制备总RNA,所得产品几乎不含DNA和蛋白质,经过分离Poly(A)~ mRNA,证明制品有合成cDNA的完整功能,方法比较简捷,适于大量制备以满足分离mRNA 之需,并讨论了此法的优缺点。 相似文献
90.
H N Qian J Feng H Cui B S Gao S L Qin T Y Fu P Wei Z Y Fu S M Gao Z Y Yang 《中华医学杂志(英文版)》1991,104(2):109-113
Monoclonal antibody 131I-COC183B2, developed in our laboratory and proved to fit for human treatment was injected intraperitoneally or subcutaneously in 13 patients. In 8 cases with i.p. injection the disease corresponded with the image, i.e. 3 primary ovarian epithelial cancers showed positive images, 1 ovarian Krukenberg tumor was negative and the other 4 negative images included 1 uterine myoma and 3 ovarian teratomas. In the subcutaneous injection group, 4 cases had ovarian carcinoma, surgery and chemotherapy. Two negative images corresponded with the clinical status-in good health, another negative case had metastatic left supraclavicular lymph node due to ovarian mucinous adenocarcinoma. The last negative image in this group was a case of benign ovarian teratoma which was proved after surgery. The 1 positive case was waiting to be proved by a scheduled third operation. The computer scintigram calculation of T/NT was 5.35 to 13.7. The results suggest that this monoclonal antibody can be used for radioimmunoimaging for the localization of ovarian carcinoma, which is not only helpful for clinical staging and differential diagnosis but is also a good follow-up method.
相似文献